Factsheets for switching to Rezolsta (darunavir/c) or Evotaz (atazanavir/c)
29 November 2016. Related: Guidelines.
Two new factsheets for doctors who are switching patients to coformulated cobicistat-boosted PIs.
Rezolsta (darunavir/cobicistat) and Evotaz (atazanavir/cobicistat) are new fixed dose combinations (FDC) combining the HIV protease inhibitors darunavir and atazanavir with the pharmacokinetic enhancer cobicistat. When switching from ritonavir-boosted darunavir or atazanavir to the respective FDCs there are multiple clinical differences that need to be considered for each patient.
This resource has been jointly produced by the Royal Free London and Chelsea & Westminster HIV teams and the University of Liverpool HIV pharmacology group.